imagine what he gets if celg buys the co. either way he is a winner and you will be just flipping another moniker on a yahoo post
lol the co is broke, reinvented itself, baker brs been stuck here for decades, ceo never materialized anything but his salary, huge debt and their pipeline (if successful) will be obsolete by the time any go to market.
clearly a true success story for a phase 1. No serious adverse events. That's what a phase one is for, safety data.
David Steensma, a leukemia specialist at Dana Farber Cancer Institute in Boston, called AG-221 “a very exciting” agent that “is showing promise to really transform this difficult type of leukemia to a much more treatable disease.” He also said mutations in IDH genes in other tumors, including the brain cancer glioblastoma multiforme, suggest the drug could have use beyond leukemia
Researchers so far have evaluated 73 patients for safety and reported that 11 died. Nine of the deaths were related to the disease while two were considered possibly associated with the treatment, including with one who died of a blood infection called sepsis. The most common side effect was fatigue, but Dr. Stein said most patients don’t report any noticeable side effects of the medicine.